Letter From DEA

National Rx Security’s Letter From the DEA

This Letter from the DEA was sent to our company President, Dan McCaffery, at the inception of National Rx Security in 1992. Mr. McCaffery met with the Office of Diversion Control within the Drug Enforcement Administration (DEA) to highlight the tamper resistant security features of our prescription pads and Rx paper. Additionally, Mr. McCaffery promoted our company’s mission to fight prescription drug abuse through the sale of our products and in community with our clients.

At National Rx Security’s beginning, we were one of the few companies producing tamper resistant prescription pads in the nation. Though the Rx pad manufacturer industry has increased over time, we stand by our commitment. Most notably, that the design, manufacture and distribution of tamper resistant prescription pads and Rx paper has always been, and will continue to be, our only business.

The following is the transcript of the letter from the DEA, thanking Mr. McCaffery for his presentation and encouraging the efforts of National Rx Security.

U.S. Department of Justice
Drug Enforcement Administration

November 9, 1992

Mr. Dan McCaffery
National Rx Security
2432 NW 63rd Street
Boca Raton, Florida 33496

Dear Mr. McCaffery:

This letter is in response to your correspondence of October 22, 1991, regarding forge resistant prescription pads. We would like to take this opportunity to thank you for the presentation made to the Office of Diversion Control, on October 21, 1992. It was very informative and well received.

The Drug Enforcement Administration (DEA) encourages and supports any programs or initiatives aimed at curtailing the diversion of licitly manufactured controlled substances into the illicit channel.

Your product offers and interesting approach to the problem of forged and stolen prescriptions. It provides prescription security as well as an avenue for prescription abuse education. However, as previously stated at the October 21, 1992, meeting, it is DEA’s policy not to endorse individual products.

We encourage your effort in the fight against pharmaceutical drug diversion. If there are further questions, please feel free to contact me at (phone number removed for confidentiality).

(Name removed for confidentiality), Chief
Liaison and Policy Section
Office of Diversion Control

Scroll Up